This past winter, hospitals and clinics across Indiana filled up with patients suffering from different respiratory illnesses that have much the same symptoms: COVID-19, flu and RSV. And many more ...

Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.

SHANGHAI, Jan 14 (Reuters) - BGI Genomics and Roche Diagnostics have rolled out tests for Alzheimer's disease in China, the companies said, in an effort to expand access to easier-to-use diagnosis ...

Used with the cobas ® 5800, 6800 and 8800 systems, cobas Respiratory 4-flex simultaneously detects and differentiates the four most common respiratory viruses, helping to ensure confidence in ...

Rules out Alzheimer's pathology in early stages to enhance diagnostic pathway efficiency Provides new opportunity to broaden access and improve referral quality Features as part of Roche's growing ...

Roche Diagnostics says it has developed blood tests to help rule out a diagnosis of Alzheimer’s disease in the broad population, thus narrowing who might be suffering from the disease. Nearly 7 ...

Roche says it's actively working with its partners to enhance mpox laboratory capacity worldwide to develop diagnostic tests to combat the outbreak. The World Health Organization (WHO) last week ...

Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of ...

ZURICH (Reuters) - Roche has struck a $1.7 billion cancer drug pact with Blueprint Medicines , it said on Tuesday, as advances in genetic testing for rare mutations drive lucrative deals for expensive ...